MalarVx files Form D for $2.5 million convertible note offering
The Seattle biotech has sold $125,000 of a planned $2.5 million offering as of August 8, 2026, with two investors so far.
MalarVx, Inc., a Seattle-based biotechnology company, filed a Form D with the SEC disclosing a new exempt securities offering. The filing lists a date of first sale of 2026-08-08 and is marked as a new notice rather than an amendment.1
The security type is described specifically as a promissory note convertible into equity.1 The company is relying on the Rule 506(b) exemption under Regulation D, according to the filing.
MalarVx set a total offering amount of $2,500,000, with $125,000 already sold and $2,375,000 remaining to be sold.1 Two investors have already invested in the offering, according to the form.1 The minimum investment accepted from any outside investor is $25,000.1
The company reported no sales commissions or finders' fees tied to the offering. Both sales commissions and finders' fees were listed as $0.1 Proceeds directed to executive officers, directors, or promoters were estimated. The filing lists $50,000, marked as an estimate, for payments to persons named as executive officers, directors, or promoters.1
The company classified itself under the biotechnology industry group and reported revenue or net asset value in the $1,000,001 to $5,000,000 range.1
The Form D was signed by Jodi Herczeg, identified in the filing as General Counsel/VP, on 2026-08-23. James Davie and Jodi Herczeg are listed in the filing as related persons serving as executive officers of the company, both based at the company's Seattle address on Eastlake Ave E.
The filing does not describe the offering as connected to a merger, acquisition, or exchange offer. The form indicates the offering is not being made in connection with a business combination transaction.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.